CFM
IMRX icon

Catalyst Funds Management’s Immuneering IMRX Stock Holding History

Catalyst Funds Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,800
Closed -$67.5K – 761
2026
Q1 		$67.5K Buy
+12,800
New +$65.6K 0.01% 521
2024
Q3 		– Sell
-5,600
Closed -$7.17K – 1445
2024
Q2 		$7.17K Buy
+5,600
New +$9.21K ﹤0.01% 994

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Catalyst Funds Management's IMRX Position: Q2 2026 in Review

Catalyst Funds Management sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 12,800 shares — an estimated $67.5K sold.

Catalyst Funds Management first reported a position in IMRX in Q2 2024 and held it in 2 quarters. The position peaked at $67.5K in Q1 2026. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Catalyst Funds Management reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 12,800 Immuneering shares in Q2 2026, an estimated $67.5K.
  • Catalyst Funds Management first reported a position in Immuneering in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Immuneering position peaked at $67.5K in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.